{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T01:53:07Z","timestamp":1777513987814,"version":"3.51.4"},"reference-count":143,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Infectious Disease Clinics of North America"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1016\/j.idc.2009.06.004","type":"journal-article","created":{"date-parts":[[2009,11,12]],"date-time":"2009-11-12T05:35:33Z","timestamp":1258004133000},"page":"1053-1075","source":"Crossref","is-referenced-by-count":44,"title":["Current Use for Old Antibacterial Agents: Polymyxins, Rifamycins, and Aminoglycosides"],"prefix":"10.1016","volume":"23","author":[{"given":"Luke F.","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.idc.2009.06.004_bib1","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0891-5520(03)00058-8","article-title":"Polymyxins: pharmacology, pharmacokinetics, pharmacodynamics, and clinical applications","volume":"17","author":"Hermsen","year":"2003","journal-title":"Infect Dis Clin North Am"},{"issue":"3","key":"10.1016\/j.idc.2009.06.004_bib2","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1128\/AAC.45.3.781-785.2001","article-title":"In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis","volume":"45","author":"Li","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.idc.2009.06.004_bib3","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1586\/14787210.5.5.811","article-title":"Polymyxin B: similarities to and differences from colistin (polymyxin E)","volume":"5","author":"Kwa","year":"2007","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"1","key":"10.1016\/j.idc.2009.06.004_bib4","doi-asserted-by":"crossref","first-page":"R27","DOI":"10.1186\/cc3995","article-title":"Toxicity of polymyxins: a systematic review of the evidence from old and recent studies","volume":"10","author":"Falagas","year":"2006","journal-title":"Crit Care"},{"issue":"6","key":"10.1016\/j.idc.2009.06.004_bib5","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1093\/jac\/dkm357","article-title":"Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review","volume":"60","author":"Zavascki","year":"2007","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"10.1016\/j.idc.2009.06.004_bib6","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1517\/13543784.17.7.973","article-title":"Re-emergence of colistin in today's world of multidrug-resistant organisms: personal perspectives","volume":"17","author":"Falagas","year":"2008","journal-title":"Expert Opin Investig Drugs"},{"issue":"8","key":"10.1016\/j.idc.2009.06.004_bib7","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1007\/s00134-005-2691-4","article-title":"Safety and efficacy of colistin in acinetobacter and pseudomonas infections: a prospective cohort study","volume":"31","author":"Reina","year":"2005","journal-title":"Intensive Care Med"},{"issue":"3","key":"10.1016\/j.idc.2009.06.004_bib8","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1128\/IAI.23.3.660-664.1979","article-title":"Polymyxin B sulfate modification of bacterial endotoxin: effects on the development of endotoxin shock in dogs","volume":"23","author":"From","year":"1979","journal-title":"Infect Immun"},{"issue":"1","key":"10.1016\/j.idc.2009.06.004_bib9","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1128\/JCM.39.1.183-190.2001","article-title":"Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines","volume":"39","author":"Gales","year":"2001","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.idc.2009.06.004_bib10","series-title":"Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing","year":"2008"},{"issue":"5","key":"10.1016\/j.idc.2009.06.004_bib11","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1086\/338782","article-title":"Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?","volume":"34","author":"Livermore","year":"2002","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2009.06.004_bib12","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1046\/j.1365-2958.2000.01956.x","article-title":"Temperature-regulated efflux pump\/potassium antiporter system mediates resistance to cationic antimicrobial peptides in Yersinia","volume":"37","author":"Bengoechea","year":"2000","journal-title":"Mol Microbiol"},{"issue":"9","key":"10.1016\/j.idc.2009.06.004_bib13","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1345\/aph.18426","article-title":"Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria","volume":"33","author":"Evans","year":"1999","journal-title":"Ann Pharmacother"},{"issue":"10","key":"10.1016\/j.idc.2009.06.004_bib14","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1086\/592577","article-title":"Pharmacokinetics of intravenous polymyxin B in critically ill patients","volume":"47","author":"Zavascki","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2009.06.004_bib15","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1055\/s-2007-996407","article-title":"Optimizing use of colistin and polymyxin B in the critically ill","volume":"28","author":"Nation","year":"2007","journal-title":"Semin Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.idc.2009.06.004_bib16","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1177\/00912700122010537","article-title":"The pharmacokinetics of colistin in patients with cystic fibrosis","volume":"41","author":"Reed","year":"2001","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.idc.2009.06.004_bib17","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s10096-001-0680-2","article-title":"Cerebrospinal fluid penetration and pharmacokinetic\/pharmacodynamic parameters of intravenously administered colistin in a case of multidrug-resistant Acinetobacter baumannii meningitis","volume":"21","author":"Jimenez-Mejias","year":"2002","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"2","key":"10.1016\/j.idc.2009.06.004_bib18","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/jac\/dki461","article-title":"Pharmacokinetics of inhaled colistin in patients with cystic fibrosis","volume":"57","author":"Ratjen","year":"2006","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.idc.2009.06.004_bib19","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/jac\/dkl512","article-title":"In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates","volume":"59","author":"Owen","year":"2007","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.idc.2009.06.004_bib20","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1093\/jac\/dkm511","article-title":"Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model","volume":"61","author":"Bergen","year":"2008","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.idc.2009.06.004_bib21","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1128\/AAC.47.3.905-909.2003","article-title":"Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model","volume":"47","author":"Gunderson","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.idc.2009.06.004_bib22","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0732-8893(02)00443-1","article-title":"Synergy of colistin with rifampin and trimethoprim\/sulfamethoxazole on multidrug-resistant Stenotrophomonas maltophilia","volume":"44","author":"Giamarellos-Bourboulis","year":"2002","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"Suppl 2","key":"10.1016\/j.idc.2009.06.004_bib23","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1086\/504486","article-title":"Novel antibiotic combinations against infections with almost completely resistant Pseudomonas aeruginosa and Acinetobacter species","volume":"43","author":"Rahal","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.idc.2009.06.004_bib24","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1179\/joc.2007.19.2.226","article-title":"In vitro synergistic activity of colistin with aminoglycosides, beta-lactams and rifampin against multidrug-resistant gram-negative bacteria","volume":"19","author":"Chitnis","year":"2007","journal-title":"J Chemother"},{"issue":"9","key":"10.1016\/j.idc.2009.06.004_bib25","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/j.1469-0691.2008.02061.x","article-title":"Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies","volume":"14","author":"Petrosillo","year":"2008","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"10.1016\/j.idc.2009.06.004_bib26","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ijantimicag.2008.04.013","article-title":"Colistin and rifampicin combination in the treatment of ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii","volume":"32","author":"Song","year":"2008","journal-title":"Int J Antimicrob Agents"},{"issue":"12","key":"10.1016\/j.idc.2009.06.004_bib27","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1046\/j.1469-0691.2000.00169.x","article-title":"In vitro and in vivo synergistic activity of colistin, rifampin, and amikacin against a multiresistant Pseudomonas aeruginosa isolate","volume":"6","author":"Tascini","year":"2000","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"10.1016\/j.idc.2009.06.004_bib28","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1128\/AAC.01101-07","article-title":"Subacute toxicity of colistin methanesulfonate in rats: comparison of various intravenous dosage regimens","volume":"52","author":"Wallace","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.idc.2009.06.004_bib29","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1177\/106002809102501101","article-title":"Toxicity of colistin in cystic fibrosis patients","volume":"25","author":"Bosso","year":"1991","journal-title":"DICP"},{"issue":"9","key":"10.1016\/j.idc.2009.06.004_bib30","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1086\/374337","article-title":"Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP","volume":"36","author":"Garnacho-Montero","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.idc.2009.06.004_bib31","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1183\/09031936.00156906","article-title":"Ventilator-associated pneumonia due to colistin susceptible-only microorganisms","volume":"30","author":"Rios","year":"2007","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.idc.2009.06.004_bib32","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ijantimicag.2006.08.024","article-title":"Intraventricular or intrathecal use of polymyxins in patients with gram-negative meningitis: a systematic review of the available evidence","volume":"29","author":"Falagas","year":"2007","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"10.1016\/j.idc.2009.06.004_bib34","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1086\/514754","article-title":"Successful treatment of ceftazidime-resistant Klebsiella pneumoniae ventriculitis with intravenous meropenem and intraventricular polymyxin B: case report and review","volume":"28","author":"Segal-Maurer","year":"1999","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.idc.2009.06.004_bib35","doi-asserted-by":"crossref","first-page":"915","DOI":"10.3171\/jns.2005.102.5.0915","article-title":"Intrathecal colistin for treatment of highly resistant pseudomonas ventriculitis. Case report and review of the literature","volume":"102","author":"Gump","year":"2005","journal-title":"J Neurosurg"},{"issue":"Suppl 2","key":"10.1016\/j.idc.2009.06.004_bib36","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1086\/504485","article-title":"Parenteral and inhaled colistin for treatment of ventilator-associated pneumonia","volume":"43","author":"Linden","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2009.06.004_bib37","first-page":"4","article-title":"Acinetobacter pneumonia: a review","volume":"9","author":"Hartzell","year":"2007","journal-title":"MedGenMed"},{"issue":"9","key":"10.1016\/j.idc.2009.06.004_bib38","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1086\/425368","article-title":"Practice guidelines for the management of bacterial meningitis","volume":"39","author":"Tunkel","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2009.06.004_bib39","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1097\/00063198-200111000-00013","article-title":"The clinical use of colistin in patients with cystic fibrosis","volume":"7","author":"Beringer","year":"2001","journal-title":"Curr Opin Pulm Med"},{"issue":"8","key":"10.1016\/j.idc.2009.06.004_bib40","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1086\/529198","article-title":"Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options","volume":"46","author":"Maragakis","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2009.06.004_bib41","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1097\/CCM.0B013E3181652FAE","article-title":"Risk factors associated with the isolation of colistin-resistant gram-negative bacteria: a matched case-control study","volume":"36","author":"Matthaiou","year":"2008","journal-title":"Crit Care Med"},{"issue":"2","key":"10.1016\/j.idc.2009.06.004_bib42","first-page":"97","article-title":"Rifaximin\u2013a novel antimicrobial for enteric infections","volume":"50","author":"Huang","year":"2005","journal-title":"J\u00a0Infect"},{"issue":"3","key":"10.1016\/j.idc.2009.06.004_bib43","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004610.pub3","article-title":"Antibiotic treatment for Clostridium difficile-associated diarrhea in adults","author":"Nelson","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.idc.2009.06.004_bib44","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1128\/AAC.49.2.627-631.2005","article-title":"Bactericidal action of gatifloxacin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis","volume":"49","author":"Paramasivan","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.idc.2009.06.004_bib45","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ijantimicag.2006.10.001","article-title":"Evaluation of an intracellular pharmacokinetic in vitro infection model as a tool to assess tuberculosis therapy","volume":"29","author":"Cappelletty","year":"2007","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"10.1016\/j.idc.2009.06.004_bib46","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1073\/pnas.61.2.667","article-title":"Interaction of rifamycin with bacterial RNA polymerase","volume":"61","author":"Wehrli","year":"1968","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.idc.2009.06.004_bib47","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/clinids\/3.1.28","article-title":"Postantibiotic suppression of bacterial growth","volume":"3","author":"Bundtzen","year":"1981","journal-title":"Rev Infect Dis"},{"issue":"Suppl 3","key":"10.1016\/j.idc.2009.06.004_bib48","doi-asserted-by":"crossref","first-page":"S412","DOI":"10.1093\/clinids\/5.Supplement_3.S412","article-title":"Rifampin: spectrum of antibacterial activity","volume":"5","author":"Thornsberry","year":"1983","journal-title":"Rev Infect Dis"},{"issue":"2","key":"10.1016\/j.idc.2009.06.004_bib49","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/jac\/20.2.197","article-title":"In-vitro susceptibility of gram-positive cocci to LY146032 teicoplanin, sodium fusidate, vancomycin, and rifampicin","volume":"20","author":"Pohlod","year":"1987","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.idc.2009.06.004_bib50","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0891-5520(05)70098-2","article-title":"Emergence of drug resistance. Impact on bacterial meningitis","volume":"13","author":"Klugman","year":"1999","journal-title":"Infect Dis Clin North Am"},{"issue":"5","key":"10.1016\/j.idc.2009.06.004_bib51","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1128\/AAC.22.5.920","article-title":"Antagonism between nafcillin or oxacillin and rifampin against Staphylococcus aureus","volume":"22","author":"Watanakunakorn","year":"1982","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 3","key":"10.1016\/j.idc.2009.06.004_bib52","doi-asserted-by":"crossref","first-page":"S481","DOI":"10.1093\/clinids\/5.Supplement_3.S481","article-title":"Rifampin in experimental endocarditis due to Staphylococcus aureus in rabbits","volume":"5","author":"Zak","year":"1983","journal-title":"Rev Infect Dis"},{"issue":"Suppl 3","key":"10.1016\/j.idc.2009.06.004_bib53","doi-asserted-by":"crossref","first-page":"S533","DOI":"10.1093\/clinids\/5.Supplement_3.S533","article-title":"Therapy for experimental endocarditis due to Staphylococcus epidermidis","volume":"5","author":"Kobasa","year":"1983","journal-title":"Rev Infect Dis"},{"issue":"4","key":"10.1016\/j.idc.2009.06.004_bib54","doi-asserted-by":"crossref","first-page":"447","DOI":"10.7326\/0003-4819-98-4-447","article-title":"Staphylococcus epidermidis causing prosthetic valve endocarditis: microbiologic and clinical observations as guides to therapy","volume":"98","author":"Karchmer","year":"1983","journal-title":"Ann Intern Med"},{"issue":"8","key":"10.1016\/j.idc.2009.06.004_bib55","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1128\/AAC.37.8.1630","article-title":"Evaluation of antimicrobial regimens for treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis","volume":"37","author":"Friedland","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.idc.2009.06.004_bib56","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/jac\/49.3.507","article-title":"Experimental study of the efficacy of vancomycin, rifampicin and dexamethasone in the therapy of pneumococcal meningitis","volume":"49","author":"Martinez-Lacasa","year":"2002","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"10.1016\/j.idc.2009.06.004_bib57","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1128\/AAC.43.10.2372","volume":"43","author":"Fitoussi","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.idc.2009.06.004_bib58","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/jac\/dkm509","article-title":"Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections","volume":"61","author":"Bassetti","year":"2008","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.idc.2009.06.004_bib59","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/MAJ.0b013e31814a586a","article-title":"Update on rifampin and rifabutin drug interactions","volume":"335","author":"Baciewicz","year":"2008","journal-title":"Am J Med Sci"},{"issue":"2","key":"10.1016\/j.idc.2009.06.004_bib60","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1365-2710.2007.00811.x","article-title":"Rifampin, a cytochrome P450 3A inducer, decreases plasma concentrations of antipsychotic risperidone in healthy volunteers","volume":"32","author":"Mahatthanatrakul","year":"2007","journal-title":"J Clin Pharm Ther"},{"issue":"8","key":"10.1016\/j.idc.2009.06.004_bib61","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1097\/QAD.0b013e3282faa71e","article-title":"High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir\/ritonavir tablets","volume":"22","author":"Nijland","year":"2008","journal-title":"AIDS"},{"issue":"4","key":"10.1016\/j.idc.2009.06.004_bib62","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004785.pub3","article-title":"Antibiotics for preventing meningococcal infections","author":"Fraser","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.idc.2009.06.004_bib63","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s10096-005-1297-7","article-title":"Prophylactic use of antibiotics for prevention of meningococcal infections: systematic review and meta-analysis of randomised trials","volume":"24","author":"Fraser","year":"2005","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2009.06.004_bib64","doi-asserted-by":"crossref","first-page":"977","DOI":"10.3201\/eid1106.050143","article-title":"Rifampin-resistant meningococcal disease","volume":"11","author":"Rainbow","year":"2005","journal-title":"Emerg Infect Dis"},{"issue":"2","key":"10.1016\/j.idc.2009.06.004_bib65","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.diagmicrobio.2006.11.022","article-title":"Detection of resistance to rifampicin and decreased susceptibility to penicillin in Neisseria meningitidis by real-time multiplex polymerase chain reaction assay","volume":"58","author":"Stefanelli","year":"2007","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2009.06.004_bib66","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1093\/infdis\/171.3.728","article-title":"Eradication of nasopharyngeal carriage of Neisseria meningitidis in children and adults in rural Africa: a comparison of ciprofloxacin and rifampicin","volume":"171","author":"Cuevas","year":"1995","journal-title":"J Infect Dis"},{"issue":"8","key":"10.1016\/j.idc.2009.06.004_bib67","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1001\/archinte.168.8.805","article-title":"Adjunctive use of rifampin for the treatment of Staphylococcus aureus infections: a systematic review of the literature","volume":"168","author":"Perlroth","year":"2008","journal-title":"Arch Intern Med"},{"issue":"1","key":"10.1016\/j.idc.2009.06.004_bib68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.37.1.1","article-title":"Use of rifampin in nonstaphylococcal, nonmycobacterial disease","volume":"37","author":"Morris","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.idc.2009.06.004_bib69","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1093\/jac\/dkm408","article-title":"Antibiotics for the eradication of Propionibacterium acnes biofilms in surgical infection","volume":"60","author":"Bayston","year":"2007","journal-title":"J Antimicrob Chemother"},{"issue":"23","key":"10.1016\/j.idc.2009.06.004_bib70","doi-asserted-by":"crossref","first-page":"e394","DOI":"10.1161\/CIRCULATIONAHA.105.165564","volume":"111","author":"Baddour","year":"2005","journal-title":"Circulation"},{"issue":"Suppl 3","key":"10.1016\/j.idc.2009.06.004_bib71","doi-asserted-by":"crossref","first-page":"S491","DOI":"10.1093\/clinids\/5.Supplement_3.S491","article-title":"Experimental chronic staphylococcal osteomyelitis in rabbits: treatment with rifampin alone and in combination with other antimicrobial agents","volume":"5","author":"Norden","year":"1983","journal-title":"Rev Infect Dis"},{"issue":"12","key":"10.1016\/j.idc.2009.06.004_bib72","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s10096-007-0378-1","article-title":"Rifampin as adjuvant treatment of gram-positive bacterial infections: a systematic review of comparative clinical trials","volume":"26","author":"Bliziotis","year":"2007","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"2","key":"10.1016\/j.idc.2009.06.004_bib73","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ajic.2006.09.005","article-title":"Oral rifampin for eradication of Staphylococcus aureus carriage from healthy and sick populations: a systematic review of the evidence from comparative trials","volume":"35","author":"Falagas","year":"2007","journal-title":"Am J Infect Control"},{"issue":"2","key":"10.1016\/j.idc.2009.06.004_bib74","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1086\/510392","article-title":"Randomized controlled trial of chlorhexidine gluconate for washing, intranasal mupirocin, and rifampin and doxycycline versus no treatment for the eradication of methicillin-resistant Staphylococcus aureus colonization","volume":"44","author":"Simor","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"7646","key":"10.1016\/j.idc.2009.06.004_bib75","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1136\/bmj.39497.500903.25","article-title":"Treatment of human brucellosis: systematic review and meta-analysis of randomised controlled trials","volume":"336","author":"Skalsky","year":"2008","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.idc.2009.06.004_bib76","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ijid.2005.11.007","article-title":"Comparison between doxycycline-rifampin-amikacin and doxycycline-rifampin regimens in the treatment of brucellosis","volume":"11","author":"Ranjbar","year":"2007","journal-title":"Int J Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.idc.2009.06.004_bib77","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1159\/000081999","article-title":"Rifaximin, a peculiar rifamycin derivative: established and potential clinical use outside the gastrointestinal tract","volume":"51","author":"Pelosini","year":"2005","journal-title":"Chemotherapy"},{"issue":"8","key":"10.1016\/j.idc.2009.06.004_bib78","first-page":"483","article-title":"In vitro antibacterial activity of rifaximin against Clostridium difficile, Campylobacter jejunii and Yersinia spp","volume":"13","author":"Ripa","year":"1987","journal-title":"Drugs Exp Clin Res"},{"issue":"11","key":"10.1016\/j.idc.2009.06.004_bib79","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/j.1469-0691.2004.00997.x","article-title":"Influence of rifaximin treatment on the susceptibility of intestinal gram-negative flora and enterococci","volume":"10","author":"DuPont","year":"2004","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"10.1016\/j.idc.2009.06.004_bib80","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1179\/joc.2002.14.3.290","article-title":"Effects of rifaximin administration on the intestinal microbiota in patients with ulcerative colitis","volume":"14","author":"Brigidi","year":"2002","journal-title":"J Chemother"},{"issue":"4","key":"10.1016\/j.idc.2009.06.004_bib81","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1086\/499950","article-title":"Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders","volume":"42","author":"Adachi","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.idc.2009.06.004_bib82","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1086\/323814","article-title":"Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind clinical trial","volume":"33","author":"DuPont","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2009.06.004_bib83","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1159\/000007580","article-title":"Rifaximin: a nonabsorbed antimicrobial in the therapy of travelers' diarrhea","volume":"59","author":"DuPont","year":"1998","journal-title":"Digestion"},{"issue":"5","key":"10.1016\/j.idc.2009.06.004_bib84","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1111\/j.1572-0241.2003.07283.x","article-title":"Therapy of travelers' diarrhea with rifaximin on various continents","volume":"98","author":"Steffen","year":"2003","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.idc.2009.06.004_bib85","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1345\/aph.1H395","article-title":"Absence of effect of oral rifaximin on the pharmacokinetics of ethinyl estradiol\/norgestimate in healthy females","volume":"41","author":"Trapnell","year":"2007","journal-title":"Ann Pharmacother"},{"issue":"6","key":"10.1016\/j.idc.2009.06.004_bib86","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1345\/aph.1K675","article-title":"Rifamycin antibiotics for treatment of Clostridium difficile-associated diarrhea","volume":"42","author":"Garey","year":"2008","journal-title":"Ann Pharmacother"},{"issue":"8","key":"10.1016\/j.idc.2009.06.004_bib87","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2146\/ajhp070077","article-title":"Current and future treatment modalities for Clostridium difficile-associated disease","volume":"65","author":"Halsey","year":"2008","journal-title":"Am J Health Syst Pharm"},{"issue":"3","key":"10.1016\/j.idc.2009.06.004_bib88","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1128\/AAC.01143-07","article-title":"Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of disease recurrence in hamsters","volume":"52","author":"Kokkotou","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.idc.2009.06.004_bib89","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1097\/01.mcg.0000225685.37465.e7","article-title":"Efficacy of rifaximin and vancomycin combination therapy in a patient with refractory Clostridium difficile-associated diarrhea","volume":"41","author":"Berman","year":"2007","journal-title":"J Clin Gastroenterol"},{"issue":"6","key":"10.1016\/j.idc.2009.06.004_bib90","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1086\/511870","article-title":"Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin","volume":"44","author":"Johnson","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2009.06.004_bib91","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1086\/520991","article-title":"Back to the future: using aminoglycosides again and how to dose them optimally","volume":"45","author":"Drusano","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.idc.2009.06.004_bib92","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1093\/jac\/dkl044","article-title":"The role of aminoglycosides in combination with a beta-lactam for the treatment of bacterial endocarditis: a meta-analysis of comparative trials","volume":"57","author":"Falagas","year":"2006","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.idc.2009.06.004_bib93","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10096-007-0389-y","article-title":"New antimicrobial agents as therapy for resistant gram-positive cocci","volume":"27","author":"Lentino","year":"2008","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2009.06.004_bib94","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1055\/s-2007-996406","article-title":"Optimizing use of aminoglycosides in the critically ill","volume":"28","author":"Rea","year":"2007","journal-title":"Semin Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.idc.2009.06.004_bib95","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.mcna.2006.07.006","article-title":"New uses for older antibiotics: nitrofurantoin, amikacin, colistin, polymyxin B, doxycycline, and minocycline revisited","volume":"90","author":"Cunha","year":"2006","journal-title":"Med Clin North Am"},{"issue":"5","key":"10.1016\/j.idc.2009.06.004_bib96","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1179\/joc.2004.16.5.437","article-title":"Antimicrobial susceptibility patterns in Pseudomonas aeruginosa: data from a multicenter Intensive Care Unit Surveillance Study (ISS) in the United States","volume":"16","author":"Friedland","year":"2004","journal-title":"J Chemother"},{"issue":"7","key":"10.1016\/j.idc.2009.06.004_bib97","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1007\/s00134-002-1313-7","article-title":"Experience with a once-daily dosing program of aminoglycosides in critically ill patients","volume":"28","author":"Buijk","year":"2002","journal-title":"Intensive Care Med"},{"issue":"3","key":"10.1016\/j.idc.2009.06.004_bib98","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0891-5520(03)00057-6","article-title":"Pharmacodynamics and dosing of aminoglycosides","volume":"17","author":"Turnidge","year":"2003","journal-title":"Infect Dis Clin North Am"},{"issue":"2","key":"10.1016\/j.idc.2009.06.004_bib99","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/jac\/32.2.215","article-title":"Postantibiotic effect of aminoglycosides on staphylococci","volume":"32","author":"Isaksson","year":"1993","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.idc.2009.06.004_bib100","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/jac\/22.1.23","article-title":"Postantibiotic effect of aminoglycosides on gram-negative bacteria evaluated by a new method","volume":"22","author":"Isaksson","year":"1988","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.idc.2009.06.004_bib101","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/clinids\/3.1.38","article-title":"Postantibiotic leukocyte enhancement: increased susceptibility of bacteria pretreated with antibiotics to activity of leukocytes","volume":"3","author":"McDonald","year":"1981","journal-title":"Rev Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2009.06.004_bib102","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/infdis\/158.1.7","article-title":"Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental pseudomonas pneumonia","volume":"158","author":"Kapusnik","year":"1988","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.idc.2009.06.004_bib103","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/jac\/dkl489","article-title":"Combined effect of pH and concentration on the activities of gentamicin and oxacillin against Staphylococcus aureus in pharmacodynamic models of extracellular and intracellular infections","volume":"59","author":"Baudoux","year":"2007","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.idc.2009.06.004_bib104","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/BF01658708","article-title":"Effect of peritoneal fluid pH on outcome of aminoglycoside treatment of intraabdominal infections","volume":"17","author":"Simmen","year":"1993","journal-title":"World J Surg"},{"issue":"6","key":"10.1016\/j.idc.2009.06.004_bib105","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1128\/AAC.14.6.927","article-title":"Anaerobic resistance of clinical isolates of Staphylococcus aureus to aminoglycosides","volume":"14","author":"Harrell","year":"1978","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.idc.2009.06.004_bib106","doi-asserted-by":"crossref","first-page":"713","DOI":"10.2165\/00003495-200161060-00001","article-title":"Aminoglycoside adaptive resistance: importance for effective dosage regimens","volume":"61","author":"Barclay","year":"2001","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.idc.2009.06.004_bib107","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1128\/AAC.35.1.117","article-title":"First-exposure adaptive resistance to aminoglycoside antibiotics in vivo with meaning for optimal clinical use","volume":"35","author":"Daikos","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.idc.2009.06.004_bib108","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/s00284-008-9123-y","article-title":"Aminoglycoside-resistance mechanisms in multidrug-resistant Staphylococcus aureus clinical isolates","volume":"56","author":"Chandrakanth","year":"2008","journal-title":"Curr Microbiol"},{"issue":"1","key":"10.1016\/j.idc.2009.06.004_bib109","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/clpt.1989.4","article-title":"Once-daily dosing decreases renal accumulation of gentamicin and netilmicin","volume":"45","author":"Verpooten","year":"1989","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.idc.2009.06.004_bib110","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1093\/infdis\/140.4.576","article-title":"The influence of dosage regimen on experimental gentamicin nephrotoxicity: dissociation of peak serum levels from renal failure","volume":"140","author":"Bennett","year":"1979","journal-title":"J Infect Dis"},{"issue":"7","key":"10.1016\/j.idc.2009.06.004_bib111","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1128\/AAC.43.7.1549","article-title":"Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity","volume":"43","author":"Rybak","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"issue":"9\u201310","key":"10.1016\/j.idc.2009.06.004_bib112","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.addr.2006.07.028","article-title":"Chronobiology and chronotoxicology of antibiotics and aminoglycosides","volume":"59","author":"Beauchamp","year":"2007","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"10.1016\/j.idc.2009.06.004_bib113","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1345\/aph.1A395","article-title":"Aminoglycoside-associated nephrotoxicity in the elderly","volume":"37","author":"Baciewicz","year":"2003","journal-title":"Ann Pharmacother"},{"issue":"2","key":"10.1016\/j.idc.2009.06.004_bib114","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2174\/1568005043340858","article-title":"Aminoglycoside nephrotoxicity","volume":"4","author":"Rougier","year":"2004","journal-title":"Curr Drug Targets Infect Disord"},{"issue":"8","key":"10.1016\/j.idc.2009.06.004_bib115","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/sj.ki.5002434","article-title":"Ototoxicity","volume":"72","author":"Rybak","year":"2007","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.idc.2009.06.004_bib116","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1172\/JCI112463","article-title":"Kinetics of gentamicin uptake and release in the rat. Comparison of inner ear tissues and fluids with other organs","volume":"77","author":"Tran Ba Huy","year":"1986","journal-title":"J Clin Invest"},{"issue":"9","key":"10.1016\/j.idc.2009.06.004_bib117","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1128\/AAC.31.9.1383","article-title":"Univariate and multivariate analyses of risk factors predisposing to auditory toxicity in patients receiving aminoglycosides","volume":"31","author":"Gatell","year":"1987","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.idc.2009.06.004_bib118","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1345\/aph.1L001","article-title":"Aminoglycoside-induced vestibular injury: maintaining a sense of balance","volume":"42","author":"Ariano","year":"2008","journal-title":"Ann Pharmacother"},{"issue":"3","key":"10.1016\/j.idc.2009.06.004_bib119","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1128\/AAC.39.3.650","article-title":"Experience with a once-daily aminoglycoside program administered to 2,184 adult patients","volume":"39","author":"Nicolau","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.idc.2009.06.004_bib120","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1128\/AAC.40.11.2494","article-title":"Validation and nephrotoxicity of a simplified once-daily aminoglycoside dosing schedule and guidelines for monitoring therapy","volume":"40","author":"Prins","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.idc.2009.06.004_bib121","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/jac\/49.3.437","article-title":"Role of aminoglycosides in the treatment of bacterial endocarditis","volume":"49","author":"Graham","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idc.2009.06.004_bib122","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002009.pub2","article-title":"Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis","volume":"3","author":"Smyth","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.idc.2009.06.004_bib123","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/01.mcp.0000245712.51514.a1","article-title":"Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis","volume":"12","author":"Ratjen","year":"2006","journal-title":"Curr Opin Pulm Med"},{"issue":"1","key":"10.1016\/j.idc.2009.06.004_bib124","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004197.pub2","article-title":"Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis","author":"Wood","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"issue":"9459","key":"10.1016\/j.idc.2009.06.004_bib125","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0140-6736(05)17906-9","article-title":"Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis\u2013the TOPIC study: a randomised controlled trial","volume":"365","author":"Smyth","year":"2005","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.idc.2009.06.004_bib126","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1517\/14656566.9.5.751","article-title":"Costs, quality of life and treatment compliance associated with antibiotic therapies in patients with cystic fibrosis: a review of the literature","volume":"9","author":"Weiner","year":"2008","journal-title":"Expert Opin Pharmacother"},{"issue":"Suppl 5 Pt 1","key":"10.1016\/j.idc.2009.06.004_bib127","first-page":"141","article-title":"Inhalation of tobramycin in patients with cystic fibrosis: comparison of two methods","volume":"58","author":"Dopfer","year":"2007","journal-title":"J Physiol Pharmacol"},{"issue":"Suppl 1","key":"10.1016\/j.idc.2009.06.004_bib128","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2165\/00148581-200709001-00003","article-title":"Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa","volume":"9","author":"Lenoir","year":"2007","journal-title":"Paediatr Drugs"},{"issue":"6","key":"10.1016\/j.idc.2009.06.004_bib129","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1136\/thx.2007.094821","article-title":"Should we stop using intravenous gentamicin in patients with cystic fibrosis?","volume":"63","author":"Goss","year":"2008","journal-title":"Thorax"},{"issue":"4","key":"10.1016\/j.idc.2009.06.004_bib130","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2165\/00003088-198713040-00002","article-title":"Antibiotic pharmacokinetics in cystic fibrosis. Differences and clinical significance","volume":"13","author":"de Groot","year":"1987","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"10.1016\/j.idc.2009.06.004_bib131","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1136\/adc.78.6.536","article-title":"Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis","volume":"78","author":"Vic","year":"1998","journal-title":"Arch Dis Child"},{"issue":"1","key":"10.1016\/j.idc.2009.06.004_bib132","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/jac\/42.1.103","article-title":"The pharmacokinetics and toxicity of once-daily tobramycin therapy in children with cystic fibrosis","volume":"42","author":"Bragonier","year":"1998","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.idc.2009.06.004_bib133","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.2165\/00003495-200060050-00006","article-title":"The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way?","volume":"60","author":"Banerjee","year":"2000","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.idc.2009.06.004_bib134","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1128\/AAC.44.4.809-813.2000","article-title":"Pharmacokinetics of tobramycin in adults with cystic fibrosis: implications for once-daily administration","volume":"44","author":"Beringer","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.idc.2009.06.004_bib135","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/jac\/48.2.325","article-title":"Serum pharmacokinetics and sputum penetration of amikacin 30 mg\/kg once daily and of ceftazidime 200 mg\/kg\/day as a continuous infusion in cystic fibrosis patients","volume":"48","author":"Byl","year":"2001","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.idc.2009.06.004_bib136","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jcf.2006.12.007","article-title":"Population pharmacokinetics of tobramycin administered thrice daily and once daily in children and adults with cystic fibrosis","volume":"6","author":"Touw","year":"2007","journal-title":"J\u00a0Cyst Fibros"},{"issue":"5","key":"10.1016\/j.idc.2009.06.004_bib137","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1159\/000104807","article-title":"Therapeutic drug monitoring of gentamicin: evaluation of five nomograms for initial dosing at Al-Amiri hospital in Kuwait","volume":"16","author":"Al-Lanqawi","year":"2007","journal-title":"Med Princ Pract"},{"issue":"2","key":"10.1016\/j.idc.2009.06.004_bib138","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2165\/00003088-199936020-00001","article-title":"Once daily aminoglycoside therapy. Is it less toxic than multiple daily doses and how should it be monitored?","volume":"36","author":"Barclay","year":"1999","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"10.1016\/j.idc.2009.06.004_bib139","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1093\/clinids\/24.5.786","article-title":"A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides","volume":"24","author":"Bailey","year":"1997","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.idc.2009.06.004_bib140","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2165\/00003088-200140110-00002","article-title":"Individualising aminoglycoside dosage regimens after therapeutic drug monitoring: simple or complex pharmacokinetic methods?","volume":"40","author":"Tod","year":"2001","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"10.1016\/j.idc.2009.06.004_bib141","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.1445-5994.1995.tb01529.x","article-title":"Experience of once-daily aminoglycoside dosing using a target area under the concentration-time curve","volume":"25","author":"Barclay","year":"1995","journal-title":"Aust N Z J Med"},{"issue":"3","key":"10.1016\/j.idc.2009.06.004_bib142","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1080\/00313029800169466","article-title":"Monitoring of serum aminoglycoside levels with once-daily dosing","volume":"30","author":"Paterson","year":"1998","journal-title":"Pathology"},{"issue":"3","key":"10.1016\/j.idc.2009.06.004_bib143","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0002-9343(02)01476-6","article-title":"Pharmacokinetic dosing of aminoglycosides: a controlled trial","volume":"114","author":"Bartal","year":"2003","journal-title":"Am J Med"},{"key":"10.1016\/j.idc.2009.06.004_bib144","first-page":"236","article-title":"Daily dosage of aminoglycosides","volume":"17","author":"Urban","year":"1997","journal-title":"Curr Clin Top Infect Dis"}],"container-title":["Infectious Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S089155200900049X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S089155200900049X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,23]],"date-time":"2020-05-23T16:03:08Z","timestamp":1590249788000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S089155200900049X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":143,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["S089155200900049X"],"URL":"https:\/\/doi.org\/10.1016\/j.idc.2009.06.004","relation":{},"ISSN":["0891-5520"],"issn-type":[{"value":"0891-5520","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}